Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen’s Aducanumab And The Case For A Medicare-Driven Clinical Trial

Feb 02 2021

• By Sarah Karlin-Smith

In Tau We Trust

Related Content

Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot

Nov 08 2020

USA FDA Gives Biogen Big Hand In Effort To Get Its Alzheimer’s Treatment On The Market

Nov 05 2020

CMS Drug Coverage Could Be Driven By Commercial Plan Decisions Under Proposal

Sep 01 2020

Medicare Coverage Policy Change Opens Up Commercial Market Pathway – If Biden Likes It

Feb 03 2021

Industry Praises CMS Final MCIT Reimbursement Rule; Urges Biden Team To Implement It

Jan 13 2021

Related Companies

Biogen, Inc.

Additional Topics

United States Pricing Debate Biologics Commercial Government Payers Reimbursement Drug Approval Standards Policy Neurology BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window